Chemokines and chemokine receptors as promoters of prostate cancer growth and progression

Critical Reviews in Eukaryotic Gene Expression

Volumn 23, Issue 1, 2013, Pages 77-91

  Salazar, Nicole ^a,b   Castellan, Miguel ^a   Shirodkar, Samir S ^a   Lokeshwar, Bal L ^a,b,c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Chemokine receptors; Chemokines; Gene regulation; Growth factor receptors; Invasion; Metastasis; Motility; Prostate cancer; Survival signaling

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CHEMOKINE RECEPTOR CXCR6; CHEMOKINE RECEPTOR CXCR7;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER RESISTANCE; CANCER SURVIVAL; HUMAN; METASTASIS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION;

CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CHEMOKINES; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION;

EID: 84875547888     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukaryotGeneExpr.2013006905     Document Type: Article

References (70)

1. American Cancer Society. Cancer facts & figures 2012. Atlanta: American Cancer Society; 2012.
2. Kim ED, Grayhack JT. Clinical symptoms and signs of prostate cancer. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, editors. Comprehensive text book of genitourinary oncology. 2nd ed. Baltimore: Lippincott Williams & Wilkins; 2000. p. 525-533.
3. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: Current standards and future prospects. J Urology. 1998;160:1220-1229.
4. Hadaschik BA, Gleave ME. Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol. 2007;25:413-419.
5. Sonpavde G, Kantoff PW. Immunotherapy for cas-tration-resistant prostate cancer. Urol Clin North Am. 2012;39:465-481.
6. Cersosimo RJ. New agents for the management of castration-resistant prostate cancer. Ann Pharmacother. 2012;46:1518-1528.
7. Muller A, Homey B, Soto H, Ge NF, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-56.
8. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Vandamme J, Walz A, Marriott D, Chan SY, Roczniak S, Shanafelt AB. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem. 1995;270:27348-27357.
9. Walz A, Peveri P, Aschauer H, Baggiolini M. Purifcaion and aminio acid sequencing of NAF, a novel neutrophil activating factor produced by monocytes. Biochem Bio-phys Res Comm. 1987;149:755-761.
10. Yoshimura T, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ, Leonard EJ. Purifcation of a human monocyte-derived nutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proce Natl Acad Sci U S A. 1987;84:9233-9237.
11. Zlotnik A, Yoshie O, Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol. 2006;7:243.
12. Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Ann Rev Immunol. 2007;25:787-820.
13. Stillie R, Farooq SM, Gordon JR, Stadnyk AW. The functional significance behind expressing two IL-8 receptor types on PMN. J Leukoc Biol. 2009;86:529-543.
14. Wang JH, Wang JC, Sun YX, Song WY, Nor JE, Want CY, Taichman RS. Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell Signal. 2005;17:1578-1592.
15. Engl T, Relja B, Blumenberg C, Muller I, Ringel EM, Beecken WD, Jonas D, Blaheta RA. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci. 2006;78:1784-1793.
16. Chinni SR, Yamamoto H, Dong Z, Sabbota A, Bonfl RD, Cher ML. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res. 2008;6:446-457.
17. Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP. Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7. Proc Natl Acad Sci U S A. 2010;107:628-633.
18. Singh RK, Lokeshwar BL. The IL-8-regulated chemo-kine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res. 2011;71:3268-3277.
19. Mustafa S, See HB, Seeber RM, Armstrong SP, White CW, Ventura S, Ayoub MA, Pfeger KDG. Identifca-tion and profiling of novel alpha(1A)-adrenoceptor-CXC chemokine receptor 2 heteromer. J Biol Chem. 2012;287:12952-12965.
20. Singh S, Singh UP, Stiles JK, Grizzle WE, Lillard JW. Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin Cancer Res. 2004;10:8743-8750.
21. Heresi GA, Wang JC, Taichman R, Chirinos JA, Regala-do JJ, Lichtstein DM, Rosenblatt JD. Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: Report of a case, review of the literature, and analysis of chemokine receptor expression. Urol Oncol. 2005;23:261-267.
22. Murphy C, McGurk M, Pettigrew J, Santinelli A, Maz-zucchelli R, Johnson PG, Montironi R, Waugh DJJ. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res. 2005;11:4117-4127.
23. Waugh DJJJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14:6735-6741.
24. Shen H, Schuster R, Lu B, Waltz SE, Lentsch AB. Critical and opposing roles of the chemolkine receptors CXCR2 and CXCR3 in prostate tumor growth. Prostate. 2006;66:1721-1728.
25. Wu Q, Dhir R, Wells A. Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. Mol Cancer. 2012;11:3.
26. Vaday GG, Peehl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate. 2006;66:124-134.
27. Wang JH, Shiozawa YS, Wang JC, Wang Y, Jung YH, Pienta KJ, Mehra R, Loberg R Taichman RS. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/ SDF-1 in prostate cancer. J Biol Chem. 2008;283:4283-4294.
28. Singh S, Singh R, Singh UP, Rai SN, Novakovic KR, Chung LWK, Didier PJ, Grizzle WE, Lillard JW Jr. Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. Int J Cancer. 2009;125:2288-2295.
29. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar EM, Radinsky R, Pettaway CA, Dinney CPN. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res. 2000;6:2104-2119.
30. Kim CH, Kunkel EJ, Boisvert J, Johnston B, Campbell JJ, Genovese MC, Greenberg HB, Butcher EC. Bonzo/ CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. J Clin Invest. 2001;107:595-601.
31. Huang XK, Chen S, Xu L, Liu YQ, Deb DK, Platanias LC, Bergan RC. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res. 2005;65:3470-3478.
32. Uehara H, Troncoso P, Johnson D, Bucana CD, Dinney C, Dong ZY, Fidler IJ, Pettaway CA. Expression of in-terleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate. 2005;64:40-49.
33. Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, O'Sullivan JM, Wilson RH, Johnson PG, Waugh DJJ. Chemotherapy-induced CXC-chemokine/CXC- chemo-kine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kB transcription and evasion of apoptosis. J Pharmacol Exp Ther. 2008;327:746-759.
34. Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI. Structure and functional expression of a human interleu-kin-8 receptor. Science. 1991;235:1278-1280.
35. Murphy PM, Tiffany HL. Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science. 1991;253:1280-1283.
36. Ahuja SK, Murphy PM. The CXC chemokines growth-regulated oncogene (GRO) alpha, GRO beta, GRO gamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human inter-leukin-8 receptor. J Biol Chem. 1996;271:20545-20550.
37. Moore BB, Arenberg DA, Stoy K, Morgan T, Addison CL, Morris SB, Glass M, Wilke C, Xue YY, Sitterding S, Kunkel SL, Burdick MD, Strieter RM. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol. 1999;154:1503-1512.
38. Huang JT, Yao JL, Zhang L, Bourne PA, Quinn AM, di Sant'Agnese, Reeder JE. Differential expression of inter-leukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol. 2005;166:1807-1815.
39. MacManus CF, Pettigrew J, Seaton A, Wilson C, Maxwell PJ, Berlingeri S, Purcell C, McGurk M, Johnston PG, Waugh DJJ. Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells. Mol Cancer Res. 2007;5:737-748.
40. Shamaladevi N, Lyn DA, Escudero DO, Lokeshwar BL. CXC receptor-1 silencing inhibits androgen-independent prostate cancer. Cancer Res. 2009;69:8265-8274.
41. Lehrer S, Diamond EJ, Mamkine B, Stone NN, Stock RG. Serum interleukin-8 is elevated in men with prostate cancer and bone metastases. Technol Cancer Res Treat. 2004;3:411.
42. Caruso DJ, Carmack AJK, Lokeshwar VB, Duncan RC, Soloway MS, Lokeshwar BL. Osteopontin and interleu-kin-8 expression is independently associated with pros-tate cancer recurrence. Clin Cancer Res. 2008;14:4111-4118.
43. Araki S, Omori Y, Lyn D, Singh K, Meinback DM, Sandman Y, Lokeshwar. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res. 2007;67:6854-6862.
44. Taichman RS, Cooper C, Keller ET, Pienta KJ, Tachman NS, McCauley LK. Use of the stromal cell-derived fac-tor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002;62:1832-1837.
45. Mochizuki H, Matsubara A, Teishima J, Mutaguchi K, Yasumoto H, Dahiya R, Usui T, Kamiya K. Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis. Biochem Biophys Res Comm. 2004;320:656-663.
46. Gupta SK, Lysko PG, Pillarisetti K, Ohlstein E, Stadel JM. Chemokine receptors in human endothelial cells -Functional expression of CXCR4 and its transcriptional regulation by infammatory cytokines. J Biol Chem. 1998;273:4282-4287.
47. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, Beider K, Avniel S, Kasem S, Galun E, Peled A. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J. 2004;18:1240-1242.
48. Sun YX, Wang JC, Shelburne CE, Lopatin DE, Cinnai-yan AM, Rubin MA, Pienta KJ, Taichman RS. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem. 2003;89:462-473.
49. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman NI, Koh-Paige AJ, Shim H, Pienta KJ, Keller ET, McCauley LK, Taichman RS. Skeletal localization and neutralization of the SDF-1(CXCL12)/ CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res. 2005;20:318-329.
50. Akashi T, Koizumi K, Nagakawa O, Fuse H, Saiki I. An-drogen receptor negatively infuences the expression of chemokine receptors (CXCR4, CCR1) and ligand-medi-ated migration in prostate cancer DU-145. Oncol Rep. 2006;16:831-836.
51. Akashi T, Koizumi K, Tsuneyama K, Saiki I, Takano Y, Fuse H. Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci. 2008;99:539-542.
52. Engl T, Relja B, Marian D, Blumenberg C, Muller I, Beecken WD, Jones J, Ringel EM, Bereiter Hahn J, Jonas D, Blaheta RA. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha(5) and beta(3) Integrins. Neoplasia. 2006;8:290-301.
53. Arya M, Patel HRH, McGurk C, Tatoud R, Klocker H, Masters J, Williamson M. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interac-tion in prostate cancer metastasis. J Exp Ther Oncol. 2004;4:291-303.
54. Windus LCE, Kiss DL, Glover T, Avery VM. In vivo biomarker expression patterns are preserved in 3D cultures of prostate cancer. Exp Cell Res. 2012;318:2507- 2519.
55. Singh S, Singh R, Sharma PK, Singh UP, Rai SN, Chung LWK, Cooper CR, Novakovic KR, Grizzle WE, Lillard JW. Serum CXCL13 positively correlates with prostatic disease, prostate-specifc antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett. 2009;283:29-35.
56. El-Haibi CP, Singh R, Sharma PK, Singh S, Lillard JW Jr. CXCL13 mediates prostate cancer cell proliferation through JNK signalling and invasion through ERK activation. Cell Prolif. 2011;44:311-319.
57. Hu WD, Zhen XM, Xiong B, Wang BC, Zhang WB, Zhou WH. CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells. Cancer Sci. 2008;99:1362-1369.
58. Wang JH, Lu Y, Wang JC, Koch AE, Zhang J, Taichman RS> CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway. Cancer Res. 2008;68:10367-10376.
59. Begley LA, MacDonald JW, Day ML, Macoska JA. CXCL12 activates a robust transcriptional response in human prostate epithelial cells. J Biol Chem. 2007;282:26767-26774.
60. Van Rechem C, Rood BR, Touka M, Pinte S, Jenal M, Guerardel C, Ramsey K, Monte D, Begue A, Tschan MP, Stephan DA, Leprince D. Scavenger chemokine (CXC motif) receptor 7 (CXCR7) is a direct target gene of HIC1 (hypermethylated in cancer 1). J Biol Chem. 2009;284:20927-20935.
61. Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, Melhem MF, Yao Z, Zhang J. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate. 2006;66:1311-1318.
62. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, Zhang J. CCR2 expression correlates with prostate cancer progression. J Cell Biochem. 2007;101:676-685.
63. Singh RJ, Sudhakar A, Lokeshwar BL. Role of chemo-kines and chemokine receptors in prostate cancer development and progression. J Cancer Sci Ther. 2010;2:89-94.
64. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res. 1999;59:5830-5835.
65. Waalkes MP. Cadmium carcinogenesis. Mutat Res. 2003;533:107-120.
66. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related infammation. Nature. 2008;454:436-444.
67. Kessenbrock K, Plaks V, Werb Z. Matrix metalloprotein-ases: regulators of the tumor microenvironment. Cell. 2010;141:52-67.
68. Kasina S, Macoska JA. The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor. Mol Cell Endocrinol. 2012;351:249-263.
69. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, Karin M. Tumour-infltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 2011;470:548-553.
70. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol. 2006;8:1369-1375.